Business Wire

Frost & Sullivan Names Luminati the 2019 Global Market Leader in the Enterprise IP Proxy Networks Market

Share

Luminati, the Israeli company that allows businesses to experience the web through the eyes of individual consumers throughout the world, today announced it has received a Market Leadership Award in the first independent analysis of the sector. Luminati’s enterprise IP proxy network (IPPN) services for global retailers, brand owners and advertising networks feature strongly in the report by analyst firm Frost & Sullivan. The report outlines a relatively new, but rapidly growing market and recognizes Luminati’s leading position in the provision of solutions that are increasingly important for businesses to remain competitive and compliant in the digital landscape. [S1]

The market for enterprise IP proxy network solutions is in its early growth stages, basically being invented by Luminati only a few years ago. With the more specialized targeting of customers by demographics and location, companies are finding it more difficult than ever to do competitive analysis and verify advertising, security, and website performance. Companies not familiar with these website practices or Internet Protocol proxy network (IPPN) solutions are at risk of gathering incorrect data and left behind technology-wise,” noted Robert Cavin, Industry Analyst, Digital Media, Frost & Sullivan.

All online businesses today rely on the market data they harvest from the Web - retailers need pricing and offers comparisons, global brands need to check and manage how their products are presented and ad networks need to verify compliance. Unfortunately, with an increasingly personalized and geo-targeted Web, searching for that data from one, or even multiple locations is unlikely to deliver any meaningful business intelligence. A once transparent and open Web has become increasingly opaque.

Luminati gives back that transparency by shedding light on what’s really going on beneath the surface of the web. Luminati’s Enterprise IP Proxy Network (IPPN) harnesses the IP addresses of over 35 million opted-in end-users worldwide to provide businesses with a real and accurate view of the web, exactly how actual consumers see it, at every geographic location. By seeing the web from any perspective, without being blocked or misled, businesses can protect their brand, research competitors, monitor for security issues, test ads and ultimately maintain a competitive edge.

The Frost & Sullivan report is encouraging reading, not only for Luminati, but as a means to alert the market to the potential for access to unique data and intelligence,” said Or Lenchner, Luminati CEO. “Ours is a relatively new industry, but one that is bringing back transparency to the Web. Ironically, the technologies that are now universally deployed to personalize the user experience are also used to severely limit legitimate research.”

That research helps companies around the world to compete on a level playing field, verify brand presentation, gather public data, test application performance, and limit fraud. That can only be a good thing in a global market but it’s critical that companies work with a responsible provider of IPPN services to protect their own reputation,” continued Lenchner.

Frost & Sullivan’s report names Luminati the 2019 global market leader in the Enterprise IP Proxy Network market, and acknowledges how the company has revolutionized the technology through its residential peer-to-peer network. What’s more, the analysis identifies Luminati’s technical leadership and strict adherence to compliance procedures as factors that will likely cement the company’s leadership position over the coming years.

Key findings from the Frost & Sullivan report include:

  • Despite the need amongst enterprises for competitor analysis, price comparison and data gathering, a significant proportion of the market is not aware of IPPN services – they risk losing revenue and customers to those businesses taking advantage of the benefits the technology delivers
  • Luminati’s services currently account for more than half of global revenues; the company is positioned as the market leader based on penetration, product line and competitive strategy
  • The top five use cases for enterprise IPPN by revenue (2018) are:
    • Price comparison
    • Ad verification
    • Fraud protection
    • Data collection
    • Brand protection
  • Revenues are expected to reach nearly USD $260M by 2025

-ENDS-

About Luminati

Founded in 2014, Luminati is the world’s largest proxy service, aimed at bringing complete transparency back to the internet. The company’s first-of-its-kind enterprise IP proxy network (IPPN) enables businesses to level the global competitive landscape by collecting online data that may otherwise mislead them, or they may be blocked from accessing.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works collaboratively with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

SURAJ MASHRU
SENIOR CAMPAIGN MANAGER
Suraj@BabelPR.com
+44-(0)-207-1993-977
www.babelpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 10:15:00 EEST | Press release

Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i

Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 10:00:00 EEST | Press release

Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vice President, Skechers Technical Performance Division. “An evolution of our legacy in running, Skechers AERO was d

The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 10:00:00 EEST | Press release

Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP and Optical Transport, Mobile Networks, Mobile Services, and Data Centres. “Network X is more than a conference—it

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 08:00:00 EEST | Press release

4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P004. “Enrolling our first patient is a pivotal step toward rewriting the treatment paradigm for knee osteoarthritis,” said Professor Francis Berenbaum, MD, PhD, Chief Medical Officer at 4Moving Biotech. “Almost 600 million people live with OA, yet no disease-modifying therapy has been done to patients. B

Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 20:06:00 EEST | Press release

Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The company’s global headquarters includes WPC certified test equipment and state-of-the-art test labs dedicated to full product lifecycle validatio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye